Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.
Cancer|Covid19
DRUG: COVID-19 vaccine
Antibody titre after vaccination, Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG), 21-28 days after completion of vaccination
Antibody titer according to chemotherapy cycle, side effects, and use of corticosteroids or antipyretics, Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG), 21-28 days after completion of vaccination|Incidence of COVID-19 infection, Incidence of actual COVID-19 infection, 6 months after completion of vaccination
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.